Vanguard Group Inc Indaptus Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding INDP
# of Institutions
21Shares Held
600KCall Options Held
0Put Options Held
0-
Investment House LLC Las Vegas, NV102KShares$115,7530.01% of portfolio
-
Geode Capital Management, LLC Boston, MA59.3KShares$67,0190.0% of portfolio
-
Strategy Asset Managers LLC45.3KShares$51,2290.02% of portfolio
-
Pine Valley Investments LTD Liability CO Marlton, NJ44.1KShares$49,8160.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny26.6KShares$30,0570.0% of portfolio
About Indaptus Therapeutics, Inc.
- Ticker INDP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,258,600
- Market Cap $9.33M
- Description
- Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...